Cargando…
Management of multidrug-resistant TB: novel treatments and their expansion to low resource settings
Despite overall progress in global TB control, the rising burden of multidrug-resistant TB (MDR-TB) threatens to undermine efforts to end the worldwide epidemic. Of the 27 countries classified as high burden for MDR-TB, 17 are in ‘low’ or ‘low–middle’ income countries. Shorter, all oral and less tox...
Autores principales: | Sloan, Derek J., Lewis, Joseph M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4755422/ https://www.ncbi.nlm.nih.gov/pubmed/26884496 http://dx.doi.org/10.1093/trstmh/trv107 |
Ejemplares similares
-
Laboratory costs of diagnosing TB in a high multidrug-resistant TB setting
por: Cates, L., et al.
Publicado: (2021) -
Multidrug-resistant Tuberculosis Management in Resource-limited Settings
por: Nathanson, Eva, et al.
Publicado: (2006) -
Low-dose amikacin in the treatment of Multidrug-resistant Tuberculosis (MDR-TB)
por: Sabur, Natasha F., et al.
Publicado: (2021) -
A UK-based resource to support the monitoring and safe use of anti-TB drugs and second-line treatment of multidrug-resistant TB
por: Potter, J L, et al.
Publicado: (2015) -
High success and low recurrence with shorter treatment regimen for multidrug-resistant TB in Nepal
por: Koirala, S., et al.
Publicado: (2021)